PhytoScience - Profile
Steven Nissen
Nissen, Steven, M.D.
Chairman, Department of Cardiovascular Medicine
Immediate Past President, American College of Cardiology, Washington, DC
Cleveland Clinic - Heart and Vascular Institute
Phone: (216) 445-6852
appointed:
1992
medical school:
University of Michigan Medical School Ann Arbor, MI
specialty training:
Fellowship - University of Kentucky Chandler Medical Center Lexington KY
Residency - University of California Davis Medical Center Sacramento CA
Internship - University of California Davis Medical Center Sacramento CA
other education:
B.S. - University of Michigan Ann Arbor MI
specialty interests:
intravascular ultrasound, digital angiography and computer image processing, coronary intensive care
Biography
Steven E. Nissen MD earned his medical degree from the University of Michigan School of Medicine in Ann Arbor. He completed Internal Medicine internship and residency at the University of California, Davis in Sacramento, and Cardiology Fellowship at the University of Kentucky Medical Center in Lexington. Early career years were spent at the University of Kentucky College of Medicine achieving a rank of Associate Professor.
Dr. Nissen came to the Cleveland Clinic in 1992. He served 9 years as Vice-Chairman of the Department of Cardiovascular Medicine and five years as Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), an organization that directs multicenter clinical trials. In 2006, he was appointed of Chairman of the Department of Cardiovascular Medicine.
Dr. Nissen�s research during the last two decades has focused on application of intravascular ultrasound (IVUS) imaging to the assessment of progression and regression of coronary atherosclerosis. He has served as International Principal Investigator for several large IVUS multi-center atherosclerosis trials.
Contributions to scientific literature include approximately 270 journal articles and 60 book chapters, with 8 manuscripts published in the NEJM and 9 others in JAMA. In recent years, he has also written on the subject of drug safety and was the author of manuscripts highlighting concerns about the Cox-2 inhibitors, muraglitazar, and rosiglitazone.
Other contributions include current service as Editor of Current Cardiology Report and Senior Consulting Editor to the Journal of the American College of Cardiology.
National positions include a 1-year term as President of the American College of Cardiology (ACC) from March 2006 to March 2007. He currently serves as a member of the Executive Committee and the Board of Trustees of the ACC. He has served several terms on the Programming Committee for ACC Annual Scientific Sessions. Dr. Nissen served as a member of the CardioRenal Advisory Panel of Food and Drug Administration (FDA) for 5yrs, and as Chairman of the final year of his membership. He continues to serve as a periodic advisor to several FDA committees as a Special Government Employee.
Dr. Nissen is a frequent lecturer before national and international meetings. He has served as visiting professor or provided Grand Rounds at nearly 100 institutions.
As a physician/scientist, Dr. Nissen consults for many pharmaceutical companies on the development of new therapies for cardiovascular disease, but maintaining his longstanding personal policy of requiring companies to donate all related honoraria directly to charity.
Dr. Nissen is also known for his role in public policy discussions, particularly in the area of drug safety. He has testified in both the Senate and House of Representatives on this issue and the need to reform the Food and Drug Administration (FDA).
Dr. Nissen was selected for the Outstanding Scientist Award by the Cleveland Clinic in 2004. He received the Outstanding Teacher Award presented by the Fellows of Cardiovascular Medicine on three occasions. He also received Award for Outstanding Contributions to Cardiovascular Research from the Gill Heart Institute of the University of Kentucky in 2004.
In 2007, Dr. Nissen was named by Time Magazine as one of the 100 most influential people in the world. He was also named in 2007 by Smart Money Magazine as one of the country’s 30 most powerful forces in business and finance.